Skip to main content

Table 3 Multivariable analysis in 266* patients with stage 4 s neuroblastoma

From: Stage 4 s neuroblastoma: features, management and outcome of 268 cases from the Italian Neuroblastoma Registry

 

No. (%) 266

PFS

p

OS

Univariate

p

Multivariate

Univariate

 

Multivariate

 

HR (95% CI)

HR (95% CI)

HR (95% CI)

p

HR (95% CI)

p

Major symptoms

 None

68 (25.4)

1

< 0.001

1

< 0.001

1

< 0.001

1

< 0.001

 Dyspnea ± Organ dysfunction

12 (4.5)

3.5 (1.2–10.2)

 

3.1 (1.1–9.3)

 

5.9 (0.8–41.6)

 

4.6 (0.6–33.2)

 

 Hepatomegaly ± Organ dysfunction

146 (54.5)

2.4 (1.2–4.7)

 

2.2 (1.1–4.3)

 

5.3 (1.2–22.6)

 

4.6 (1.1–19.8)

 

 Hepatomegaly + Dyspnea (± Organ dysfunction)

40 (14.9)

5.5 (2.6–11.7)

 

5.5 (2.6–11.8)

 

24.4 (5.7–104.4)

 

24.1 (5.6–103.4)

 

Treatment era

 1979–1984

25 (9.4)

1

0.202#

1

0.355#

1

0.041#

1

0.049#

 1985–1999

116 (43.6)

1.3 (0.6–2.7)

 

1.4 (0.7–3.0)

 

1 (0.4–2.4)

 

1.2 (0.5–2.8)

 

 2000–2013

125 (47.0)

0.8 (0.4–1.8)

 

0.9 (0.4–2.0)

 

0.5 (0.2–1.3)

 

0.5 (0.2–1.3)

 

Gender

 Male

154 (57.9)

1

0.209

1

0.707

1

0.013

1

0.091

 Female

112 (42.1)

0.8 (0.5–1.2)

 

0.8 (0.5–1.3)

 

0.5 (0.2–0.9)

 

0.6 (0.3–1.1)

 

Age, days

 0–29

60 (22.6)

1

0.077

1

0.637

1

0.011

1

0.639

 30–365

206 (77.4)

0.6 (0.4–1.0)

 

0.9 (0.5–1.5)

 

0.4 (0.2–0.8)

 

0.9 (0.4–1.6)

 

Abdominal mass

 None

232 (87.2)

1

0.052

1

0.751

1

0.006

1

0.813

 Yes

34 (12.8)

0.5 (0.2–1.1)

 

1.2 (0.4–3.6)

 

0.1 (0.0–1.0)

 

0.7 (0.1–8.4)

 
  1. Abbreviations. PFS progression-free survival, OS overall survival, HR hazard ratio, CI confidence interval
  2. *, excluding 2 patients presenting with organ dysfunction as only major symptom
  3. #, test for trend